Market Place
Sourcing Support
Compass Therapeutics Biomarker Data on CTX-471 at 39th SITC
08 Nov 2024 //
GLOBENEWSWIRE
Compass Therapeutics Announces Poster At Immunotherapy Meeting
04 Oct 2024 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in Upcoming Investor Events
03 Sep 2024 //
GLOBENEWSWIRE
Compass Therapeutics Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
07 Aug 2024 //
GLOBENEWSWIRE
Compass Therapeutics Completes Enrollment For CTX-009 Study
06 Aug 2024 //
GLOBENEWSWIRE
Compass At Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Compass Therapeutics Announces CEO Transition
28 May 2024 //
GLOBENEWSWIRE
Compass Ctx-471 Phase 1 Data: Cd137 Antitumor In Pd-(L)1 Progressive
23 May 2024 //
GLOBENEWSWIRE
Compass Therapeutics To Participate In H.C. Wainwright BioConnect Conference
14 May 2024 //
GLOBENEWSWIRE
Compass Therapeutics Reports Q1 2024 Results, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Compass gets US FDA fast track for its bispecific DLL4/VEGF-A antibody, CTX-009
27 Apr 2024 //
PHARMABIZ
Compass Gets FDA Fast Track For CTX-009 + Pacli in Pre-Treated Biliary Cancer
25 Apr 2024 //
GLOBENEWSWIRE
Compass begins patient dosing in phase 1 study of CTX-8371 solid tumours
17 Apr 2024 //
PHARMABIZ
Compass Therapeutics Doses First Patient in Phase 1 Study of CTX-8371
16 Apr 2024 //
GLOBENEWSWIRE
Compass Therapeutics Posters At Cholangiocarcinoma Conf 2024
12 Apr 2024 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
10 Apr 2024 //
GLOBENEWSWIRE
Compass Therapeutics shows Tumor Elimination Data at the AACR
09 Apr 2024 //
GLOBENEWSWIRE
Compass Therapeutics Reports 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Compass to Participate in the Leerink Partners Global Biopharma Conference
29 Feb 2024 //
GLOBENEWSWIRE
Compass Announces Publication of CTX-8371 Preclinical Data in OncoImmunology
28 Feb 2024 //
GLOBENEWSWIRE
Compass Therapeutics Provides Corporate Update
05 Jan 2024 //
GLOBENEWSWIRE
Compass Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in Upcoming Investor Events
07 Nov 2023 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in Upcoming Investor Events
30 Aug 2023 //
GLOBENEWSWIRE
Compass Therapeutics Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
22 Jun 2023 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in Upcoming Investor Events
01 Jun 2023 //
GLOBENEWSWIRE
Compass Therapeutics Reports 1Q FYR and Provides Corporate Update
04 May 2023 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
26 Apr 2023 //
GLOBENEWSWIRE
Compass Therapeutics to Participate in the Stifel 2023 Virtual Oncology Days
19 Apr 2023 //
GLOBENEWSWIRE
Compass to Participate in the Cantor Fitzgerald Future of Oncology Symposium
28 Mar 2023 //
GLOBENEWSWIRE
Compass Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Compass to Participate in the SVB Securities Global Biopharma Conference
02 Feb 2023 //
GLOBENEWSWIRE
Compass Announces that the PII Data of CTX-009 in Combination with Paclitaxel
19 Jan 2023 //
GLOBENEWSWIRE
Compass Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009
06 Jan 2023 //
GLOBENEWSWIRE
Compass Announces Presentation of Results from Phase 2 study of CTX-009
15 Dec 2022 //
GLOBENEWSWIRE
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471
01 Dec 2022 //
GLOBENEWSWIRE
Compass to Present at the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Compass Therapeutics to Present at Upcoming Investment Conferences
08 Nov 2022 //
GLOBENEWSWIRE
Compass Therapeutics to Present at H.C. Wainwright Global Investment Conference
09 Sep 2022 //
GLOBENEWSWIRE
Compass Tx to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
02 Aug 2022 //
GLOBENEWSWIRE
Compass Tx Reports Q2 2022 Financial Results and Provides Corporate Update
01 Aug 2022 //
GLOBENEWSWIRE
Compass Tx to Present at the 2022 Jefferies Global Healthcare Conference
31 May 2022 //
GLOBENEWSWIRE
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Conference
23 May 2022 //
GLOBENEWSWIRE
Compass Therapeutics Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Compass Tx to Present at the Bank of America Securities 2022 Conference
05 May 2022 //
GLOBENEWSWIRE
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009
04 May 2022 //
GLOBENEWSWIRE
Compass Tx to Host Conference Call Highlighting Clinical Data from CTX-009
03 May 2022 //
GLOBENEWSWIRE
Compass Therapeutics Announces Appointment of Two New Directors to its Board
26 Apr 2022 //
GLOBENEWSWIRE
Compass Therapeutics Presents Data on CTX-8371 at the 2022 AACR
08 Apr 2022 //
GLOBENEWSWIRE
Compass Therapeutics Announces Presentation on CTX-8371 at 2022 AACR
30 Mar 2022 //
GLOBENEWSWIRE
Compass Tx Reports Q4 and Full Year 2021 Financial Results
21 Mar 2022 //
GLOBENEWSWIRE
Handok scores FDA nod to test anticancer drug in phase 2 trial
24 Jan 2022 //
KOREABIOMED
FDA Clears Compass` IND for Phase 2 Study of CTX-009
20 Jan 2022 //
GLOBENEWSWIRE
Compass to Present at the Piper Sandler Healthcare Conference
22 Nov 2021 //
BUSINESSWIRE
Compass Reports Q3 2021 Financial Results and Provides Corporate Update
12 Nov 2021 //
BUSINESSWIRE
Compass Announces Pricing of Approximately $125M Public Offering of Common Stock
01 Nov 2021 //
BUSINESSWIRE
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a
01 Nov 2021 //
BUSINESSWIRE
CTX-009 Clinical Data Presented Today at 2021 AACR-NCI-EORTC
08 Oct 2021 //
BUSINESSWIRE
